Estimated Effectiveness of 2024-2025 COVID-19 Vaccination Against Severe COVID-19
JAMA Network Open · 03.02.2026 · 9 (2) · e2557415
DOI: 10.1001/jamanetworkopen.2025.57415 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JAMA Network Open, online erschienen am 03.02.2026. Verfasst von Kevin C Ma und 50 weiteren Autor:innen. Beteiligte Einrichtung: Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Preven…. Hauptthemen laut MEDLINE: COVID-19 Vaccines, COVID-19, Vaccine Efficacy, SARS-CoV-2. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS.
Abstract (Originalsprache)
Importance As SARS-CoV-2 JN.1 lineage descendants continue to evolve, evaluating COVID-19 vaccine effectiveness (VE) against severe COVID-19 remains important to guide vaccination strategies.
Objective
To estimate the VE of the 2024-2025 COVID-19 vaccines against COVID-19–associated hospitalization and severe in-hospital outcomes overall and by time since dose (7-89, 90-179, and ≥180 days), JN.1 descendant lineage (KP.3.1.1, XEC, LP.8.1), and spike protein mutations associated with immune evasion. Design, Setting, and Participants This multicenter, test-negative, case-control study conducted by the Investigating Respiratory Viruses in the Acutely Ill Network included adult patients (aged ≥18 years) hospitalized between September 1, 2024, and April 30, 2025, at 26 hospitals in 20 US states. Case patients presented with COVID-19–like illness and positive SARS-CoV-2 nucleic acid or antigen test results; control patients had COVID-19–like illness but tested negative for SARS-CoV-2. Exposure Receipt of a 2024-2025 COVID-19 vaccine at least 7 days before illness onset. Main Outcomes and Measures Main outcomes were COVID-19–associated hospitalization and severe in-hospital outcomes (supplemental oxygen therapy, acute respiratory failure, intensive care unit admission, and invasive mechanical ventilation or death). Logistic regression was used to estimate the odds of vaccination in case and control patients, adjusting for demographics, clinical characteristics, and enrollment region. The VE was estimated as (1 – adjusted odds ratio) × 100%.
Results
A total of 8493 patients (median [IQR] age, 66 [54-76] years; 4338 female [51.1%]), including 1888 case patients with COVID-19 (among whom 951 [50.4%] had successful whole-genome sequencing, including 348 [36.6%] with KP.3.1.1, 218 [22.9%] with XEC, and 134 [14.1%] with LP.8.1 infections) and 6605 control patients were enrolled. Vaccine effectiveness against COVID-19–associated hospitalization was 40% (95% CI, 27%-51%), and protection was sustained through 90 to 179 days after vaccination. Vaccine effectiveness was higher against the most severe outcome of invasive mechanical ventilation or death at 79% (95% CI, 55%-92%). It was 49% (95% CI, 25%-67%) against hospitalization with KP.3.1.1, 34% (95% CI, 4%-56%) against XEC, and 24% (95% CI, −19% to 53%) against LP.8.1, with increasing median time since dose receipt among vaccinated case patients due to sequential circulation patterns (60, 89, and 141 days, respectively). The VE was similar against lineages with spike protein S31 deletion (41% [95% CI, 22%-56%]) and T22N and F59S substitutions (37% [95% CI, 9%-57%]). Conclusions and Relevance In this multicenter, case-control analysis of VE, 2024-2025 COVID-19 vaccines may have provided protection against hospitalizations and severe in-hospital outcomes as multiple JN.1 descendant lineages circulated. Monitoring COVID-19 VE, including stratifying by SARS-CoV-2 lineage and spike protein mutations, remains important to guide COVID-19 vaccine composition and recommendations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
- Department of Internal Medicine, University of Michigan, Ann Arbor.
- Department of Microbiology and Immunology, University of Michigan, Ann Arbor.
- Department of Emergency Medicine, Yale University School of Medicine, New Haven, Connecticut.
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora.
- Department of Pulmonary/Critical Care Medicine, Intermountain Medical Center, Murray, Utah.
Förderung
- NIGMS NIH HHS
Zitieren
APA
Ma, K. C., Webber, A., Lauring, A. S., Bendall, E., Papalambros, L. K., Safdar, B., Ginde, A. A., Peltan, I. D., Brown, S. M., Gaglani, M., Ghamande, S., Columbus, C., Mohr, N. M., Gibbs, K. W., Hager, D. N., Prekker, M. E., Gong, M. N., Mohamed, A., Johnson, N. J., …, & Investigating Respiratory Viruses in the Acutely Ill (IVY) Network (2026). Estimated Effectiveness of 2024-2025 COVID-19 Vaccination Against Severe COVID-19. JAMA Network Open, 9(2), e2557415. https://doi.org/10.1001/jamanetworkopen.2025.57415
Vancouver
Ma KC, Webber A, Lauring AS, Bendall E, Papalambros LK, Safdar B, et al. Estimated Effectiveness of 2024-2025 COVID-19 Vaccination Against Severe COVID-19. JAMA Network Open. 2026;9(2):e2557415. doi:10.1001/jamanetworkopen.2025.57415
BibTeX
@article{Ma2026,
author = {Ma, Kevin C and Webber, Alexander and Lauring, Adam S and Bendall, Emily and Papalambros, Leigh K and Safdar, Basmah and Ginde, Adit A and Peltan, Ithan D and Brown, Samuel M and Gaglani, Manjusha and Ghamande, Shekhar and Columbus, Cristie and Mohr, Nicholas M and Gibbs, Kevin W and Hager, David N and Prekker, Matthew E and Gong, Michelle N and Mohamed, Amira and Johnson, Nicholas J and Khan, Akram and Hough, Catherine L and Duggal, Abhijit and Wilson, Jennifer G and Qadir, Nida and Chang, Steven Y and Mallow, Christopher and Busse, Laurence W and Kwon, Jennie H and Exline, Matthew C and Vaughn, Ivana A and Ramesh, Mayur and Mosier, Jarrod M and Leis, Aleda M and Harris, Estelle S and Baughman, Adrienne and Cornelison, Sydney A and Blair, Paul W and Johnson, Cassandra A and Lewis, Nathaniel M and Ellington, Sascha and Rice, Todd W and Grijalva, Carlos G and Talbot, H Keipp and Casey, Jonathan D and Halasa, Natasha and Chappell, James D and Zhu, Yuwei and Self, Wesley H and Dawood, Fatimah S and Surie, Diya and Investigating Respiratory Viruses in the Acutely Ill (IVY) Network, Investigating Respiratory Viruses in the Acutely Ill (IVY) Network},
title = {Estimated Effectiveness of 2024-2025 COVID-19 Vaccination Against Severe COVID-19},
journal = {JAMA Network Open},
year = {2026},
volume = {9},
number = {2},
pages = {e2557415},
doi = {10.1001/jamanetworkopen.2025.57415}
}
EUVIMED